GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,425.00p
   
  • Change Today:
      11.00p
  • 52 Week High: 1,671.00
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,086.30m
  • Volume: 7,848,350
  • Market Cap: £58,230m
  • RiskGrade: 129

GSK's RSV vaccine accepted for regulatory review by EMA

By Iain Gilbert

Date: Friday 13 Jun 2025

LONDON (ShareCast) - (Sharecast News) - Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older.
The FTSE 100-listed group noted that Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease.

GSK said a European regulatory decision was expected to be reached during H126 and stated it was continuing to seek expanded indications for its RSV vaccine in other countries, including the US and Japan.







Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,425.00p
Change Today 11.00p
% Change 0.78 %
52 Week High 1,671.00
52 Week Low 1,264.00
Volume 7,848,350
Shares Issued 4,086.30m
Market Cap £58,230m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.18% below the market average47.18% below the market average47.18% below the market average47.18% below the market average47.18% below the market average
39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average
Price Trend
14.52% above the market average14.52% above the market average14.52% above the market average14.52% above the market average14.52% above the market average
39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average
Income
74.86% above the market average74.86% above the market average74.86% above the market average74.86% above the market average74.86% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
31.65% below the market average31.65% below the market average31.65% below the market average31.65% below the market average31.65% below the market average
62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average

What The Brokers Say

Strong Buy 3
Buy 2
Neutral 16
Sell 3
Strong Sell 0
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 09-Jul-2025

Time Volume / Share Price
14:44 1 @ 1,424.00p
14:44 3 @ 1,424.00p
14:44 1 @ 1,424.00p
14:45 0 @ 1,422.50p
16:19 1,138,051 @ 1,407.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page